36,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
18 °P sammeln
  • Broschiertes Buch

Currently, drugs that vary in structure and mechanism of action are used to treat atherosclerosis. However, most of these drugs do not always produce the desired effect, and long-term use is associated with the development of side effects and complications. In this regard, the search for and study of new anti-atherosclerotic drugs is of great interest and is an important issue in the pharmacotherapy of atherosclerosis. One such drug is Firutas, which contains phytin, rutin, and ascorbic acid. The aim of the study was to investigate the effect of Firutas in comparison with nicotinic acid on…mehr

Produktbeschreibung
Currently, drugs that vary in structure and mechanism of action are used to treat atherosclerosis. However, most of these drugs do not always produce the desired effect, and long-term use is associated with the development of side effects and complications. In this regard, the search for and study of new anti-atherosclerotic drugs is of great interest and is an important issue in the pharmacotherapy of atherosclerosis. One such drug is Firutas, which contains phytin, rutin, and ascorbic acid. The aim of the study was to investigate the effect of Firutas in comparison with nicotinic acid on lipid metabolism and LPO in experimental atherosclerosis. Studies have shown that Firutas surpasses nicotinic acid in terms of its lipotropic and antiatherogenic effects, which is explained by the presence of rutin and ascorbic acid in the drug's composition. These bioligands have antioxidant effects and stimulate the conversion of cholesterol into bile acids, increasing lipase production and destroying excess TG. Firutas surpasses the well-known hypolipidemic drug nicotinic acid.
Autorenporträt
Ziyaeva Shakida Tulaevna, candidata a doctora en medicina, profesora adjunta del Departamento de Farmacología del Instituto Médico Pediátrico de Tashkent. Tashkent.